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The goal of this study is to establish the in vivo impact of a by-product of salicylic 
acid,  5-cloro-2-hidroxy-azotyl-sulfamoil-phenyl  benzamyde  synthesis  product 
(5ClSA-SA), synthesized at the Technical University, Faculty of Industrial Chemistry 
of Timisoara, on some parameters of energetic metabolism. The experimental results 
shows that the synthesis product has induced a strong significant increase (p<0.01) 
of glycemia compared to tests, in direct relation with administration period and a 
fluctuation  of  cholesterol  values  with  decrease  followed  by  strong  significant 
increase  (p<0.01)  compared  to  tests.  Glycemia  and  plasmatic  cholesterol  values 
were  situated  between  physiological  limits.  Triglycerides  registered  strong 
significant increases (p<0.01) in direct relation with administration period, over the 
physiological limits.  
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Introduction 
 
The researches pursued the effect of in vivo administration of 5ClSA-SA 
synthesis product, which is amide of 5 chlorosalycilic acid with sulphanilamide on 
glycemia, cholesterol and triglycerides values. 
 
Materials and Methods 
 
The study was done on 28 Wistar rats, grouped in four batches: 2 test batches 
C1 and C2 and two experimental batches E1 and E2. To the experimental batches 
was  intraperitoneally  administrated  0.44  mg/kg  m.c.  of  5ClSA-SA  for  5, 
respectively, 7 consecutive days. To the test batches was administrated the same 
quantities of distilled water (0.3 ml). The 5 ClSA-SA administrated dose had 1/10 
DL50 salicylamide constituent.   795
Blood was sampling at 24h since the fifth administration from C1 and E1 
batches, and at 24h since the seventh administration from C2 and E2 batches. 
The  determination  of  glucose,  cholesterol  and  triglycerides  was  made  on 
VET SCREEN tester. 
 
Results and Discussions 
 
Experimental results were statistic operated through ANOVA method and 
student test and are presented in tables 1, 2, 3 and graph 1.  
 
Table 1 
Average values of glycemia (mg/dL) on experimental and test groups. 
 
Group  x ± Sx  D.S  Confidence level 95% 
C1  101.3 ± 0.88  3.23  3.97 
C2  99.86 ± 1.30  3.44  3.97 
E1  130.43 ±0.72*  1.90  3.97 
E2  136.43 ± 0.89*  7.55  3.97 
*p < 0.01 
 
Table 2 
Average values of cholesterol (mg/dL) on experimental and test groups. 
 
Group  x ± Sx  D.S  Confidence level 95% 
C1  61.00 ± 1.89  5.08  4.79 
C2  62.08 ± 1.94  5.13  4.79 
E1  47.71 ±0.81*  2.14  4.79 
E2  71.01 ± 1.80*  4.76  4.79 
*p < 0.01 
 
Table 3 
Average values of triglycerides (mg/dL) on experimental and test groups. 
 
Group  x ± Sx  D.S  Confidence level 95% 
C1  112.08 ± 4.11  9.12  24.58 
C2  113.14 ± 3.53  9.34  24.58 
E1  255.86 ±5.63*  14.90  24.58 
E2  299.43 ± 9.91*  26.22  24.58 
*p < 0.01 
Glycemia  values  presented  strong  significant  increases  compared  to  test 
(p<0.01)  (E1/C1  :+28.76%;  E2/C2  :  +36.62%  )  in  relation  with  administration 
period, but not in direct ratio; the values was situated in physiological limits [10].   796
The differences registered between 5 and seven administration were not significant 
(p>0.05). 
Studies done with by-products of salicylic acid, aspirin being one of them, 
show up that in high doses they can determine hyperglycemia and glucosury, this 
substances can declutch the oxidative phospfolirality [11, 12]. The administrated 
dose has determinate the glycemia increase without his values passing over the 
normal limits given by the literature [10]. 
 
0
50
100
150
200
250
300
mg/dl
Glycemia Cholesterol Triglyceride
C
1
C
2
E
1
E
2
 
Graph 1. Glycemia, cholesterol and triglycerides variation on experimental and 
test groups 
 
The administration of synthesis product has induced the cholesterol values 
fluctuation,  that  registered  decrease  followed  by  the  strong  significant  increase 
(p<0.01) compared to test (E1/C1: -21.78%, respectively E2/C2 :+14.5%), but in 
physiological limits [7,10]. Administration on rats of salicylamide (basis nucleus of 
synthesis product) has induces the decrease of cholesterol compared to test but in 
physiological limits (unpublished personal data), and in others experiments with 
sulfamidic  derivatides,  was  registered  an  increase  of  plasmatic  cholesterol 
concentration [3]. Carboxyl or hydroxyl groups substitution change the efficiency 
and toxicity od salicylates compounds [4]. 
Triglycerides  values  registered  strong  significant  increases  (p<0.01) 
compared to test (E1/C1: +128.28%; E2/C2: +164.65%) as all as to physiological 
limits [10]. Glucose excess favors the triglycerides synthesis and inhibited the fat 
acids release, the liver being involved in fat acids circle [11]. The liver is the main 
target of drugs toxicity, xenobiotics and oxidative stress. The oxidative stress is one 
of  the  important  mechanisms  of  chemical  hepatotoxicity  [2].  Hepatotoxicity 
induced by 5ClSA-SA was confirmed by the increase of seric transaminases in the 
experimental studies done with this product [9]. Also have a short life, the reactive 
species of oxygen acts on all biologically active compounds: nucleic acids, proteins 
and amino acids, lipids, glucides [1, 2]. 
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Conclusions 
 
Administrated in vivo, the 5ClSA-SA synthesis product has determinate: 
·  The  increase  of  glycemia  values  in  direct  relation  with  administration 
period  and  plasmatic  cholesterol  fluctuation,  the  registered  values  being 
situated in physiological limits; 
·  The  strong  significant  increase  (p<0.01)  of  plasmatic  triglycerides 
compared to test and physiological limits.  
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